Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key

Syndax Pharmaceuticals shows strong Revuforj-driven growth, narrowing losses, and AML upside. Read the latest analysis on SNDX stock here.